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SUMMARY 
Obesity is a growing life-style related health problem, and is often accompanied by 
dyslipidemia, insulin resistance and inflammation. This may in turn lead to hyperinsulinemia, 
increased risk of non-alcoholic fatty liver disease, type 2 diabetes mellitus and cardiovascular 
disease. Together, these abnormalities have been clustered into the metabolic syndrome.  
The present thesis focuses on two modified fatty acids, tetradecylthioacetic acid (TTA) 
and tetradecylselenoacetic acid (TSA), with a biochemical and mechanistic angle to the 
description and possible therapeutic options of obesity related disorders and risk factors of the 
metabolic syndrome and cardiovascular disease. As major regulators of lipid metabolism and 
their involvement in glucose metabolism and inflammation, the peroxisome proliferator-
activated receptors (PPARs; PPARα, PPARδ, PPARγ) have been in focus in these studies. 
We have shown that through increased fatty acid oxidation, TTA may prevent the 
development of fatty liver induced by tamoxifen, a drug commonly used in patients with 
breast cancer. Furthermore, TTA had lipid lowering effects in patients with type 2 diabetes 
mellitus, through mechanisms seeming to involve PPARα and PPAR activation, and 
increased mitochondrial fatty acid oxidation. The role of PPARα in TTA mediated effects 
was investigated in PPARα deficient mice, and revealed that TTA was able to stimulate fatty 
acid oxidation in mice lacking PPARα, indicating that PPARα is involved in but not essential 
for the lipid lowering effects of TTA. In cell culture PPAR activation studies we confirmed 
that TTA may stimulate the activity of all PPARs. Moreover, we found that PPARγ 
coactivator (PGC)-1 is a potent PPAR coactivator, and that TTA further induced the PGC-1 
mediated coactivation of PPARδ. Thus, it seems reasonable to believe that the activity of both 
PPARα and PPARδ, with a substantial contribution of nuclear receptor coactivators, PGC-1 
in special, may be conductive to TTA’s mechanism of action. 
 Studies with TSA suggest that it exert potent antioxidant, antiinflammatory and 
hypolipidemic properties, potentially involving PPAR-related mechanisms. Antioxidants 
protect against oxidative stress and inflammation, which, in combination with hyperlipidemia, 
are important mediators of atherogenesis. Based on this, it is tempting to hypothesize that 
TSA could be an interesting antiatherogenic approach to atherosclerotic disorders. 
 Altogether the present thesis demonstrates that TTA and TSA may have a possible 
therapeutic potential in obesity related disorders and risk factors of the metabolic syndrome 
and cardiovascular disease. Their mechanism of action seems to include the action of PPARs, 
with contribution of nuclear receptor coactivators. 
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INTRODUCTION 
This thesis presents a biochemical and mechanistic angle to the description and possible 
therapeutic options of some of the factors related to obesity and the metabolic syndrome. This 
introduction will present the relevant disorders, followed by a more detailed introduction to 
the molecular participants that may play a role in regulation of these disorders and thus being 
potential therapeutic targets.  
 
Obesity and the metabolic syndrome 
Obesity is created by a positive energy balance, which is when energy intake exceeds energy 
utilization, and is a growing life-style related health problem. Obesity is defined as body mass 
index (BMI) >30 kg/m2, and overweight as 25 kg/m2 < BMI < 30 kg/m2. In many countries in 
Europe, more that 50% of the population is defined as being overweight, while up to 30% are 
defined as being obese (1). 
 The metabolic abnormalities that often accompany obesity include dyslipidemia, 
hypertension, impaired glucose tolerance, insulin resistance and inflammation. These 
abnormalities may in turn lead to hyperinsulinemia and an increased risk of non-alcoholic 
fatty liver disease (NAFLD), type 2 diabetes mellitus (T2DM) and cardiovascular disease 
(CVD) (2). Together, these abnormalities have been clustered into the metabolic syndrome. 
The World Health Organisation defines the metabolic syndrome as the coincidence of two or 
more of the following features; central obesity, elevated level of plasma triacylglycerols, 
hypertension, microalbuminuria, impaired glucose regulation or insulin resistance (3). Thus, 
the metabolic syndrome may be regarded as an obesity- and lifestyle-related disease. 
 
Obesity and inflammation 
Metabolism and the inflammatory response are integrated processes which under normal 
conditions are beneficial for the maintenance of good health, but under conditions of 
metabolic challenge this interaction can be damaging. Obesity is characterised by a state of 
chronic low-level inflammation in the adipose tissue, with an accumulation of macrophages 
and an upregulation of a variety of inflammatory and stress-response genes (4). 
The link between obesity and inflammation was first established by Hotamisligil et al. 
who demonstrated a positive correlation between adipose tissue mass and the expression of 
the proinflammatory tumour necrosis factor-α (TNFα) (5). Later, the adipose tissue has been 
established as a major secretory organ, secreting several different proteins, collectively termed 
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adipokines. Adipokines linked to the inflammatory response include cytokines (e.g. TNFα, 
interleukins) and acute phase proteins (e.g. C-reactive protein, fibrinogen) (6). 
 
Insulin resistance and type 2 diabetes mellitus 
To protect the body against hypoglycaemia during fasting and against a too high glucose level 
after a high-carbohydrate meal, homeostatic mechanisms are in place to maintain blood 
glucose levels within a very narrow range. This is achieved mainly through 
gluconeogenesis/glucose production by the liver and through peripheral glucose uptake by 
skeletal muscle, heart muscle and adipose tissue.  
 Insulin resistance and T2DM are associated with visceral obesity and large amounts of 
adipose tissue. As fat accumulates in adipose tissue there is an ongoing increase in the levels 
of plasma fatty acids, leading to increased fatty acid exposure to non-adipose tissues. The 
fatty acids may induce insulin resistance in muscle by inhibiting insulin-dependent glucose 
uptake and intracellular glucose utilization (7) as well as by altering insulin signalling and 
thereby reducing insulin-stimulated glucose transport (8). The fatty acids also stimulate 
hepatic overproduction of glucose (9). Pro-inflammatory adipokines from adipose tissue also 
interfere with insulin signalling pathways and contribute to the development of insulin 
resistance and T2DM (4).  
 The risk of CVD is increased in patients with T2DM (10, 11). Therefore, it is 
recommended that traditional CVD risk factors, dyslipidemia being the most important, is 
treated and carefully monitored in patients with T2DM (12).  
 
Atherosclerosis and cardiovascular disease 
Atherosclerosis is a progressive process responsible for diseases of the heart and blood 
vessels, collectively termed CVDs. Several risk factors are associated with the development 
of atherosclerosis and CVD, and they coincide with the disorders related to obesity and the 
metabolic syndrome: hyperlipidemia, high low density lipoprotein (LDL)-cholesterol levels, 
low high density lipoprotein (HDL)-cholesterol levels, T2DM, hypertension, inflammation 
and oxidative stress (13, 14).  
 The atherosclerotic process is initiated by infiltration and accumulation of LDL-
cholesterol within the arterial wall. This results in oxidation of LDL particles, endothelial 
alterations, inflammatory response and accumulation of cholesterol within macrophages. The 
presence of these cholesterol-rich macrophages defines the earliest pathological lesion, 
referred to as fatty streak (14). Fatty streaks are not occlusive and cause no overt symptoms, 
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but may progress into more advanced and complicated lesions called atherosclerotic plaque. 
The atherosclerotic plaque consists of foam cells, necrotic cells and accumulating amounts of 
lipids, surrounded by smooth-muscle cells and a fibrous cap. Activated immune cells 
accumulate within the lesion and induce a more severe inflammatory response that reduces 
the stability of the plaque and may lead to rupture and occlusion of the artery, heart attack and 
stroke (13, 14). 
 
Non-alcoholic fatty liver disease 
Fatty liver is considered as the hepatic expression of the metabolic syndrome (15). The 
development of fatty liver is a consequence of fatty acid accumulation in the hepatocytes, and 
causative factors include hyperlipidemia, obesity and T2DM (16, 17). At the time of 
diagnosis, most patients with NAFLD have few or no symptoms of liver disease, and 
moderate increase in serum aminotransferases is the most common and often the only 
laboratory abnormality found in these patients (18). NAFLD include a wide spectrum of liver 
injuries, which may proceed from uncomplicated fat accumulation to more severe injury with 
inflammation and loss of liver function, or hepatocellular carcinoma.  
 Contributory mechanisms that have been suggested for NAFLD include insulin 
resistance, and an imbalance between the enzyme systems that regulate the uptake, synthesis, 
oxidation and transport of fatty acids (19), leading to increased accumulation of fatty acids 
within the hepatocytes.  
Unfortunately, drug-induced fatty liver also occurs, and represents a challenge to the 
pharmaceutical industry and for the physicians. Tamoxifen is an example of a drug used in 
treatment of breast cancer that may lead to fatty liver and visceral fat accumulation (20, 21). 
 
Modified fatty acids 
Fatty acids are carboxylic acids with hydrocarbon chains that are saturated, mono- or 
polyunsaturated. The length and degree of saturation of the hydrocarbon chain largely 
determine the properties of the fatty acids and compounds of which they are a part. 
Almost 20 years ago, a group of modified fatty acids were developed in order to test a 
hypothesis related to peroxisome proliferation (22). This was the start of the still ongoing 
expedition revealing and exploring the pleiotropic effects of tetradecylthioacetic acid (TTA; 
C14-S-acetic acid). TTA is a modified fatty acid with a sulphur atom inserted in 3-position in 
the carbon backbone (Figure 1). The chemical properties of TTA are similar to natural 
saturated fatty acids with comparable chain length, however, the metabolism and metabolic 
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effects of TTA are distinctive. TTA is converted to CoA thioesters like natural fatty acids, it 
can also be delta-9 desaturated (23) and elongated (24), but due to the sulphur atom TTA 
cannot be β-oxidised and are instead sulphur- and ω-oxidised to small dicarboxylic acids (25). 
As a ligand for the peroxisome proliferator-activated receptors (PPARs) (26, 27) TTA 
stimulate the expression of several PPAR target genes, which regulate several aspects of lipid 
and glucose metabolism. The pleiotropic effects of TTA include increased mitochondrial 
proliferation and fatty acid oxidation as well as reduced plasma lipid levels, ultimately leading 
to reduced obesity and improved insulin sensitivity (25). Additionally, TTA is demonstrated 
to inhibit LDL-oxidation and lipid peroxidation (25, 28), and to have antiinflammatory 
properties through regulation of cytokine release (25, 29). 
Another modified fatty acid, tetradecylselenoacetic acid (TSA; C14-Se-acetic acid), 
was developed in an attempt to find a stronger antioxidant than TTA (28). Selenium is a 
stronger reducing agent than sulphur, therefore TSA was synthesized by inserting a selenium 
atom in the 3-position of the carbon backbone (Figure 1). As with TTA, this modification 
makes TSA resistant to fatty acid -oxidation. TSA is far less studied that TTA, but as 
hypothesised, the stronger antioxidant properties of TSA was confirmed in studies performed 
in vitro (28). 
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Figure 1: Structure of one natural and two modified fatty acids. 
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Lipid metabolism 
Uptake and transport 
Lipids belong to a chemically diverse group of fatty acid containing compounds, such as 
phospholipids and triacylglycerols, with diverse functions such as maintaining membrane 
integrity and fluidity, and serving as metabolic fuel to provide energy. Lipids also play crucial 
roles as regulators of cellular functions by acting as ligands, enzyme coactivators, cell 
membrane-anchors or intracellular messenger molecules.  
Dietary fatty acids are usually esterified as triacylglycerols. In the intestine, the action 
of water-soluble lipases converts triacylglycerols into free fatty acids, which diffuse into the 
intestinal epithelial cells before they are reconverted to triacylglycerol and incorporated with 
cholesterol and apoproteins (apo) to form lipoproteins called chylomicrons. Lipoproteins are 
spherical particles containing a hydrophobic lipid core and a hydrophilic protein surface. 
Lipoproteins are classified according to their density, which is defined by their various 
combinations of lipids and proteins. 
Through the blood stream chylomicrons are transported to liver, adipose tissue, 
skeletal muscle and the heart. Lipoprotein lipase hydrolyses the triacylglycerols to free fatty 
acids, which are taken up in the target tissues where they are either oxidised to provide energy, 
or reesterified for storage as triacylglycerols. The remnant chylomicrons are subsequently 
taken up by the liver (Figure 2). Very low density lipoproteins (VLDL) are produced in the 
liver and secreted into the blood stream for transport to extrahepatic tissues, where lipoprotein 
lipase in the capillaries releases free fatty acids from the VLDL triacylglycerols. The loss of 
triacylglycerols converts VLDL to smaller remnant VLDL, or intermediate density 
lipoproteins (IDL). Some of the IDL is taken up in the liver, through LDL receptor, or 
remains in the blood stream where it undergoes further triacylglycerol hydrolysis, resulting in 
cholesterol rich LDL. LDL is taken up in liver and extrahepatic tissues through binding to 
LDL receptor (Figure 2). Cholesterol is transported from extrahepatic tissues to the liver in 
HDL, in a process called reverse cholesterol transport. Nascent HDL is produced in the liver 
or the intestine and contains very little cholesterol. In the process of forming a mature 
spherical HDL, cholesterol is transported from extrahepatic tissues and into the nascent HDL. 
Lecithin-cholesterol acyltransferase esterifies free cholesterol in the nascent HDL and 
converts it into a mature HDL. HDL-cholesterol is delivered to the liver and may be secreted 
in the bile (Figure 2). 
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Figure 2: Schematic overview of the main pathways for lipoprotein mediated lipid transport. 
CM, chylomicron; IDL, intermediate density lipoprotein; LCAT, Lecithin-cholesterol acyltransferase; LDL, low 
density lipoprotein; LPL, lipoprotein lipase; (n)HDL, (nascent) high density lipoprotein; TG, triacylglycerol; 
VLDL, very low density lipoprotein. 
 
 
Before fatty acids that are delivered by the lipoproteins can be utilized by the cells, they need 
to be transported over the plasma membrane. As of today, two modes of cellular uptake of 
fatty acids are presented; passive diffusion over the plasma membrane, and protein-mediated 
transport. In recent years there has been more focus on the protein-mediated transport, and the 
process of diffusion over the plasma membrane has been considered quantitatively less 
important (30).  The fatty acid transporters that have been identified include the plasma 
membrane fatty acid binding protein (31), fatty acid translocase/CD36 (32-34), and a group of 
6 fatty acid transport proteins that are expressed in a tissue specific manner and show 
different transport capacities (35-37). These proteins may all act alone or in combination with 
each other in manners that may differ in various tissues (30). Although the physical 
mechanisms of the protein-mediated fatty acid transport are not yet fully elucidated, the 
process is considered as highly regulated (30). 
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Once inside the cell, the fatty acids are transported to other sub-cellular compartments 
by the cytoplasmic fatty acid binding protein (38). The hydrophilic cytoplasmic environment 
is not suitable for diffusion of fatty acids, and the fatty acids are therefore embedded in the 
hydrophobic core of the fatty acid binding protein, which then facilitate the intracellular 
transport between membranes (39). A common target for the intracellular fatty acid transport 
is the mitochondria, which is the major site for fatty acid -oxidation, although -oxidation 
also occurs in peroxisomes.  
 
Activation and Oxidation 
Before mitochondrial fatty acid oxidation the fatty acids must be activated by the attachment 
of coenzyme A (CoA) through an energy-rich thioester bond with the fatty acid carboxyl 
group. The esterification is mediated by acyl-CoA synthetase (ACS), an enzyme present in 
many cells and which exists in several variants with different fatty acid specificities (40). 
Long chain fatty acids are activated by long chain ACS in the outer mitochondrial membrane 
before they can be transported over the mitochondrial membrane by the activities of carnitine 
palmitoyltransferase (CPT)-1 and CPT–2 (Figure 3). CPT-1 in the outer mitochondrial 
membrane facilitates the exchange of the fatty acyl group from CoA to carnitine and is 
frequently described as the rate limiting step of mitochondrial -oxidation (41). Thereby the 
fatty acyl-carnitine crosses the inner mitochondrial membrane via the carnitine/acylcarnitine 
translocase. On the inside of the inner membrane, CPT-2 facilitates the formation of fatty 
acyl-CoA by the exchange of carnitine with CoA (Figure 3). The transport of short and 
medium chain fatty acids over the mitochondrial membranes occurs independently of the 
carnitine system, and they are activated to acyl-CoAs by short- and medium-chain ACS in the 
mitochondrial matrix (42) (Figure 3). 
Once inside the mitochondrial matrix, the fatty acyl-CoA may undergo -oxidation. In 
each subsequent -oxidation cycle, the fatty acyl-CoA is shortened by two carbons, yielding 
acetyl-CoA and a chain shortened fatty acyl-CoA (Figure 3). In the case of odd-chained fatty 
acids, one mole of propionyl-CoA is produced for each mole odd-chained fatty acids. A 
complete oxidation of acetyl-CoA to CO2 occurs via the citric acid cycle together with 
donation of electrons to the respiratory chain and ATP production. 
  Transport of fatty acids into peroxisomes is independent of carnitine, and the 
fatty acids seem to be transported over the peroxisomal membrane as acyl-CoAs. The 
peroxisomal -oxidation process is similar to the mitochondrial process (Figure 3), although 
the enzymes are not the same (43). Acyl-CoA oxidase (ACO) regulates the first and rate-
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limiting step of peroxisomal -oxidation, which is considered as a chain-shortening and 
partial degradation pathway for very long chain fatty acids. Due to the lack of a citric acid 
cycle, the complete degradation to CO2 can not occur in the peroxisomes (44). Chain 
shortened fatty acids are rather exported out of the peroxisomes to the mitochondria for 
further oxidation (44) (Figure 3). 
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Figure 3: Mitochondrial and peroxisomal fatty acid -oxidation. 
* Short and medium chain fatty acids, as well as ** long chain fatty acids cross the mitochondrial membrane for 
-oxidation. Very long chain fatty acids are chain-shortened in the peroxisomes and exported to the 
mitochondria for complete degradation. ACS; acyl-CoA synthetase; CAT, carnitine/acylcarnitine translocase; 
CoA, coenzyme A; CPT-1/2, carnitine palmitoyltransferase-1/2; FA, fatty acid ; IM, inner membrane; OM, outer 
membrane. 
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The nuclear receptor superfamily 
Nuclear receptors (NRs) comprise a big superfamily of ligand-activated transcription factors 
that stimulate the expression of target genes involved in metabolism, development and 
reproduction. The NRs are activated by a great variety of ligands, they show a variable degree 
of ligand specificity and one receptor may interact with several different ligands. Receptors 
for which there are yet no identified ligands are called orphan receptors. 
The NR family members share a similar domain structure. The domains are designated 
A-F from the N-terminal region to the C-terminal (Figure 4). The A/B domain region is not 
well conserved among family members. This region modulates the receptor’s promoter- and 
cell-specific activity, and the difference between receptor subtypes normally lies in this region. 
The A/B region of many receptors harbours an activation function (AF)-1 domain through 
which transcriptional activity is regulated ligand-independently. Region C harbours the DNA 
binding domain (DBD) which is the most conserved domain of the NR superfamily. It confers 
the ability to activate the transcription of target genes by binding specifically to hormone 
response elements (HREs) in their promoter region. The variable D region serves as a hinge 
between the DBD and the ligand binding domain (LBD), allowing rotation of the DBD. This 
rotation is essential in receptor conformational changes associated with ligand binding. The 
LBD, region E/F, is also highly conserved in the NR superfamily, but still differs enough to 
allow specific ligand recognition. Structure analyses have demonstrated a conserved structure, 
formed by 12 α-helices, that form a cavity which functions as a ligand binding pocket (45). 
The LBD binds ligands with high specificity, and performs several functions regulated by 
ligand binding. These functions include interaction with heat-shock proteins, homo- and 
hetero-dimerisation and transcriptional activity. Binding of antagonists may block these 
functions. The AF-2 domain is present in the C-terminal end of the LBD, and is responsible 
for ligand-dependent transcriptional activation (46). 
 Based on evolutionary analysis of the conserved domains, the NRs have been divided 
into six different subfamilies (47) and later given a unified nomenclature (48), Table 1. Some 
receptors are further divided into subtypes which may differ in terms of ligand preference, 
tissue distribution and/or target genes of which they regulate transcription. 
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Table 1: The 6 subfamilies/classes of the nuclear receptor superfamily, their abbreviation and subtypes, unified nomenclature, selection of ligands and major field of 
function.  
Class Name  Abbreviation Nomenclature Ligand Major field of function 
Thyroid hormone receptor TRα,  NR1A1, 2 Thyroid hormone Thyroid hormone response in differentiation, growth, 
metabolism, physiology 
Retinoic acid receptor RARα, , γ NR1B1, 2, 3 Retinoic acid Embryonic development 
Peroxisome proliferator-activated 
receptor 
PPARα 
PPARδ/ 
PPARγ 
NR1C1α 
NR1C2δ 
NR1C3 
Fatty acids, fibrates, WY14.643 
Fatty acids, L165.041 
Fatty acids, prostaglandins, thiazolidinediones, 
BRL49653 
Lipid and glucose metabolism 
Reverse erbA Rev-erbα,  NR1D1, 2 Orphan Cell proliferation and physiology 
RAR-related orphan receptor RORα 
ROR, γ 
NR1F1α 
NR1F2, 3 
Cholesterol, cholesteryl sulphate 
Retinoic acid Cell survival in the central nervous system 
Liver X receptor LXRα,  NR1H1, 2 Oxysterols Cholesterol homeostasis 
Farnesoid X receptor FXRα 
FXR 
NR1H4α 
NR1H4 
Bile acids, fexaramine 
Lanosterol Bile acid homeostasis 
1 
Vitamin D receptor VDR NR1I1 1-25(OH)2 vitamin D3 Calcium homeostasis, bone development and 
mineralization, cell growth and differentiation 
Hepatocyte nuclear factor 4 HNF4α 
HNF4γ 
NR2A1 
NR2A2 
Fatty acyl-CoA thioesters 
Orphan Liver development 
Retinoid X receptor RXRα, , γ NR2B1, 2, 3 9-cis-retinoic acid Embryonic patterning, organogenesis, differentiation, 
heterodimer partner for other NRs 
Testis receptor TR2 
TR4 
NR2C1 
NR2C2 
Orphan 
Orphan Negative modulator of other nuclear receptors 
Tailless TLL NR2E2 Orphan Neuronal development 
2 
Chicken ovalbumin upstream promoter-
transcription factor 
COUP-TFI, II NR2F1, 2 Orphan Peripheral nervous system development, angiogenesis, 
vascular remodelling, heart development  
Estrogen receptor ERα 
ER 
NR3A1 
NR3A2 
Estradiol, tamoxifen, raloxifene 
Estradiol 
Maintenance of the reproductive, cardiovascular, 
musculoskeletal and central nervous systems 
Estrogen-related receptor ERRα 
ERR, γ 
NR3B1α 
NR3B2, 3 
Orphan 
Diethylstilbestrol, 4-OH tamoxifen Lipid metabolism 
Glucocorticoid receptor  GR NR3C1 Glucororticoids Development, metabolism, immune response 
Mineralcorticoid receptor MR NR3C2 Aldosterone, spirolactone Electrolyte and fluid balance in the kidney 
Progesterone receptor PR NR3C3 Progesterone Reproduction 
3 
Androgen receptor AR NR3C4 Testosterone Development and function of male reproductive organs 
4 Nerve growth factor-induced factor B NGFI-B NR4A1 Orphan Stress stimuli response, apoptotic stimuli, signalling in the 
hypothalamic-pituitary axis. 
Steroidogenic factor 1 SF-1 NR5A1 Orphan Mammalian sexual development, differentiation of 
steroidogenic tissues 
5 
Liver receptor homologous protein 1 LRH1 NR5A2 Orphan Steroid, bile acid and cholesterol metabolism 
6 Germ cell nuclear factor GCNF NR6A1 Orphan Transcriptional repressor, vertebrate embryogenesis 
17
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In order to promote transcription, NRs bind through their DBD to HREs in the 
promoter region of their target genes. Two HRE consensus sequences have been identified. 
The consensus sequence AGAACA is mainly recognised by steroid receptors (class 3; Table 
1), whereas AGG/TTCA serves as a consensus recognition motif for the remaining NRs (49). 
Some receptors bind as monomers to HREs, but most receptors bind as homo- or 
heterodimers to HREs composed of two core motifs. The arrangement and spacing between 
the motifs are determinants in conferring selectivity and specificity. The dimeric HRE half-
sites can be configured as palindromes ( ), inverted palindromes ( ) or direct repeats 
( ) (reviewed in (49)). 
 
 
AF2
hPPARα DBD hinge LBD
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DBD hingehPPARδ
1 72 137 215 441
LBD
hPPARγ1 DBD hinge
1 110 175 251 477
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1 140 205 281 50730
LBD
DBD hinge LBD
A/B C D E/F
Nuclear 
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AF2
AF2
AF2
AF2
AF1
AF1
AF1
AF1
AF1
NH2– –COOH
 
 
Figure 4: The structural and functional domains of a general nuclear receptor and of PPARs. 
A-F denotes the different NR domain regions. The numbers indicate amino acid residues. AF1/2, activation 
function 1/2; DBD, DNA binding domain; LBD, ligand binding domain; hPPAR, human peroxisome 
proliferator-activated receptor. 
 
 
The peroxisome proliferator-activated receptors; PPARα, PPARδ, PPARγ 
The PPARs are class 1 members of the NR superfamily, Table 1. Three PPAR subtypes have 
been identified, PPARα (50-52), PPARδ (also called PPAR) (51, 53, 54) and PPARγ (51, 
54, 55). Three different PPARγ mRNA exist, which are produced by differential use of three 
promoters and alternative splicing of three 5’ exons. However,  the translation of PPARγ1 and 
PPARγ3 mRNA result in the same protein (56), while PPARγ2  mRNA codes for a protein 
with 30 extra amino acids in the N-terminal region. The two PPARγ isoforms are however 
19 
demonstrated to share similar response to several different PPARγ specific ligands (57, 58). 
As common for the NR family members, the PPARs also have a modular structure consisting 
of several functional domains, where the LBD and DBD are well conserved (Figure 4).  
 
Tissue distribution 
The PPAR expression level varies in different tissues, and in some tissues the PPARs are 
coexpressed. PPARα is highly expressed in metabolically active tissues, including liver, heart, 
kidney, skeletal muscle, brown fat and large intestine. PPARγ1 and γ2 are abundant in adipose 
tissue and present at lower levels in skeletal muscle. In addition, PPARγ1 is found in liver, 
macrophages and heart. PPARδ is expressed in a wide range of tissues, with relatively higher 
levels in brain, adipose tissue and skin (58, 59). 
 
PPAR function 
The PPARs stimulate the transcription of a great variety of genes, including those involved in 
almost all aspects of lipid metabolism, glucose and energy balance, inflammation, 
differentiation and proliferation (Table E), as reviewed in (59-62). The presence of a 
functional PPAR response element (PPRE) in the promoter region of the gene classifies it as a 
PPAR target gene. However, some genes could also be classified as PPAR dependent, as their 
gene-regulation is reported to be dependent upon PPAR, although a functional PPRE in their 
promoter region is not yet identified (60).  
 The PPAR system is complex, and in addition to having their own specified function 
and set of target genes, their function, tissue distribution and range of target genes may 
overlap (Table 2). However, there are several ways by which the PPAR tissue and target gene 
specificity are regulated. First of all, a differential tissue distribution controls tissue specific 
PPAR action. In tissues where PPARs are coexpressed, PPAR subtype specific ligands 
contribute to control PPAR subtype specificity. Also, the PPRE sequence, including the 5’-
flanking extension, confer a level of PPAR subtype specific control (63). 
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Table 2:  PPAR function in inflammation, lipid and energy metabolism in selected tissues. 
 
 PPARα (61, 64) PPARδ (62, 65, 66) PPARγ (59, 64) 
Liver FA oxidation  
FA uptake  
HDL lipoprotein  
Inflammation  
VLDL production  
FA synthesis  
Glc output  
 
 
Skeletal muscle FA oxidation  
FA uptake  
Glc intolerance/insulin resistance  
TG lipolysis  
Glc utilization  
FA oxidation  
FA transport  
Mitochondrial respiration   
Thermogenesis  
Slow-twitch fibres  
 
White adipose tissue  FA oxidation  
Thermogenesis  
FA transport  
Differentiation  
Lipid storage  
Brown adipose tissue  FA oxidation  
FA transport  
Thermogenesis  
 
Artery / Blood vessel 
 
Reverse cholesterol transport  
Inflammation  
HDL cholesterol  
Inflammation  
 
Inflammation  
FA, fatty acid; Glc, glucose; HDL, high density lipoprotein; TG, triacylglycerol; VLDL, very low density 
lipoprotein 
 
 
PPAR ligands 
PPARs are defined as generous hosts, capable of specifically interacting with more than one 
ligand. The PPAR subtype specific ligand preference is achieved through the difference 
between their LBDs. 
Naturally occurring PPAR ligands include fatty acids and fatty acid derived 
compounds (Table 3). Synthetic ligands are also identified (Table 3), and some of them have 
been used in treatment of diabetes or hyperlipidemia. Several lipid-lowering agents, including 
fibrates and WY14.643, are classified as PPARα ligands (54, 67). The anti diabetic 
thiazolidinediones, such as rosiglitazone/BRL49653, are characterised to be PPARγ ligands 
(68, 69). In a series of novel compounds, L165.041 turned out to be a selective PPARδ 
agonist with hypolipidemic effects (70, 71). 
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PPARs form a permissive heterodimer with retinoid X receptor (RXR), which means 
that either partner can regulate the transcriptional activity of the DNA-bound complex by 
interacting with its agonist, on its own or when both partners are ligand-bound. RXR is the 
receptor for 9-cis-retinoic acid (72). 
In addition to ligand-dependent activation, phosphorylation by the various kinases also 
affects PPAR activity in both ligand–dependent and –independent manners that depend on the 
PPAR subtype and cellular context, reviewed in (73). 
 
 
Table 3: List of selected endogenous and synthetic PPAR ligands. 
 PPARα PPARδ PPARγ 
Endogenous 
ligands 
USFAs (54, 67, 74-77) 
SFAs (75) 
8(S)-HETE (74-76) 
USFAs (54, 74, 75, 77) 
SFAs (75) 
8(S)-HETE (77) 
USFAs (54, 74, 76, 77) 
9- and 13-HODE (78) 
15d-PGJ2 (78-80) 
 
Synthetic 
ligands 
Fenofibrate (81) 
Clofibrate (67, 75) 
Cipofibrate (67, 75) 
Gemfibrozil (67, 75) 
WY14.643 (54, 67, 75, 77) 
TTA (26, 27, 75) 
GW501516 (82) 
L165.041(70) 
TTA (26, 27) 
BRL49653 (68, 69) 
Pioglitazone (68, 83) 
Ciglitazone (68, 83) 
TTA (26, 27) 
BRL49653, Rosiglitazone; HETE, hydroxyeicosatetraenoic acid; HODE, hydroxyoctadecadienoic acid; 15d-PG 
J2, 15-deoxy-12,14-prostaglandin J2; SFAs, saturated fatty acids; TTA, tetradecylthioacetic acid; USFAs, 
unsaturated fatty acids 
 
 
DNA binding properties 
For DNA binding, the PPARs depend on RXR as a hetero-dimer binding partner. They bind 
to a PPRE, which is an imperfect direct repeat of two core recognition motifs spaced by one 
nucleotide (DR-1 motif). A consensus PPRE sequence has been given as 5-AGGTCA A 
AGGTCA-3 (84). PPARs bind to the upstream extended core hexamer of the DR-1, whereas 
RXR occupies the downstream motif (85). This consensus sequence is common for the other 
class 1 members of the NR superfamily, but the spacing between the core recognition motifs 
(AGGTCA) may vary and thereby contribute to receptor specific recognition of the response 
element. In contrast to the RXRα homodimer which also binds to the DR-1 motif, the 
PPARα/RXRα heterodimer was demonstrated to be highly dependent on a 5’-flanking 
extension sequence (C A/G A/G A A/T CT) (86). The presence of this 5’ sequence favoured 
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DNA binding of the heterodimer compared to the homodimer. Also PPAR subtype-specific 
PPRE recognition is mainly dependent on this 5’-flanking extension, and PPARα and PPARδ 
seem to be more dependent on this extension sequence than on a perfect DR-1 PPRE 
sequence as compared to PPARγ (63).  
 
Nuclear receptor coactivators 
The activity and function of PPARs and other NRs are strongly dependent on the interaction 
with coregulator proteins, which includes both corepressors and coactivators. These proteins 
associate with NRs, and while corepressors attenuate the NR transcriptional activity, 
coactivators, which will be in focus in this thesis, promote their transcriptional activity.  
The coactivators represent a diverse group of proteins, but common for most of them 
is their NR interacting domain, containing LXXLL α-helical motifs, where L represents the 
amino acid leucine, and X is any amino acid (87). The stabilisation of the AF-2 helical 
domain in activated NRs creates a charge clamp and a hydrophobic pocket in the LBD, which 
define the coactivator interaction domain (88). The charge clamp is made from two conserved 
charged amino acid residues (lysine and glutamate) in the LBD that positions the LXXLL 
motif so that the leucine residues may pack into the intervening hydrophobic pocket.  
While the charge clamp and amino acid residues in the hydrophobic pocket are 
conserved among the NRs, several NRs still show specific preferences towards different 
coactivators. This may be explained by the ligand dependent conformational changes in the 
AF-2 domain of the NR. But also, the number of LXXLL motifs, as well as their length and 
orientation relative to each other, varies among coactivators (87), and may account for some 
of the specificity. Additionally, the LXXLL motifs are divided into four classes, depending on 
their flanking amino acids (89, 90), and different NRs have preferences for different classes of 
LXXLL motifs. 
 The coactivators are also diverse in means of their function; they posess diverse 
enzymatic activities that contribute to transcriptional activation. Through histone 
acyltransferase, methyltransferase and chromatin remodelling activities, coactivators may 
relax the tightly packed chromatin structure and enhance the accessibility of other 
transcription factors to allow genes to be transcribed. Through their splicing control function, 
coactivators are also involved in splicing (maturation, removal of introns) of the newly 
transcribed gene. Additionally, coactivators may function as signal integrators, transferring 
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cell-surface signals further into the cell. These aspects are reviewed by D.M. Lonard and B.W. 
O’Malley (91). 
 
PPAR interaction with coactivators 
The unliganded PPAR/RXR heterodimer interacts with corepressors that suppress the 
transcriptional activity. In the unliganded state the receptors are proposed to exist in a 
conformational equilibrium where the LBD structure is variable. Activation by ligand binding 
releases the corepressors and stabilises the AF-2 helical domain in a conformation that is 
permissive for coactivator interaction (88, 92, 93). The coactivators can actuate or enhance 
NR activity through remodelling of the histone and chromatin structure and/or bridging to the 
basal transcription machinery (91). Several different coactivators have been described, that 
are able to interact with the PPARs (94). The coactivators are expressed in a tissue specific 
manner and their expression level may be influenced by physiological status, which again 
may contribute to the tissue-specific PPAR activity. Additionally, structure analyses and other 
in vitro assays have suggested that the PPAR structure is altered in a ligand-specific way, 
resulting in distinct interactions with coactivators, allowing distinct ligand-specific 
downstream effects (88, 92, 93, 95-97).   
Of PPAR interacting coactivators relevant for this thesis, are two coactivators from the 
steroid receptor coactivator (SRC) family, SRC-1 and SRC-2, as well as PPARγ coactivator 
(PGC)-1α (termed PGC-1 hereafter) from the PGC-1 family. These coactivators will be more 
closely presented in the following sections. 
 
The steroid receptor coactivators 
The steroid receptor coactivator family (SRC), comprise three members; SRC-1 (98), SRC-2 
(also called TIF2 or GRIP1) (99, 100) and SRC-3 (also called AIB1, pCIP or ACTR) (101-
104), which are all widely expressed in many cell types and tissues. The members of the SRC 
family share a common domain structure, with a conserved N-terminal domain for DNA 
interaction and interaction with other coactivators. Centrally located are three copies of the 
conserved LXXLL motifs, through which they interact with ligand activated NRs. At the C-
terminal these receptors have a transcriptional activation function. In this region the SRCs 
interact with other coactivators through another set of LXXLL motifs (105). Through these 
interactions the SRC coactivators becomes part of multiunit complexes consisting of proteins 
with the capacity of modifying histones, remodelling chromatin and interacting with the basal 
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transcription machinery (102, 106, 107). Additionally, a weak histone acetyl transferase 
function is present in the C-terminal end of SRC-1 (108) and SRC-3 (102).  
Several studies have demonstrated the ability of SRC-1 (88, 95, 109-111) and SRC-2 
(95, 110-112) to interact with and to coactivate all the different PPARs. In 1998 Nolte et al. 
(88) showed the crystal structure of SRC-1 bound to PPARγ, showing the coactivator 
interaction domain and the charge clamp, which is believed to be essential for most 
NR/coactivator interactions. The interactions between PPARs and coactivators have been 
demonstrated to be both dependent and independent of exogenous ligands. 
The biological function of the SRCs includes roles in development, fertility and 
hormone response. In addition, studies have revealed a role of  SRC-1, SRC-2 and SRC-3 in 
energy homeostasis and adipogenesis (113, 114), as depicted in Table 4. These studies show 
that while SRC-1 -/- mice have reduced energy expenditure and tend to be obese, the mice 
lacking SRC-2 have increased adaptive thermogenesis and are protected against high fat diet 
induced obesity (114). Studies of SRC-3 demonstrate an essential role of this coactivator in 
adipocyte differentiation in that it regulates several genes involved in the differentiation 
process (113). 
 
 
Table 4: The role of coactivators in energy metabolism and mitochondrial function in selected tissues. 
 SRC-1 
(114) 
SRC-2 
(114) 
SRC-3 
(113, 115) 
PGC-1 
(116-120) 
Liver 
 
FA oxidation  FA oxidation   FA oxidation   
Gluconeogenesis  
 
Muscle    Mitochondrial biogenesis  
Oxidative phosphorylation  
Thermogenesis  
FA oxidation  
White adipose tissue 
 
 
Thermogenesis    Adipogenesis  Adipogenesis   
Brown adipose tissue Thermogenesis  Thermogenesis  Thermogenesis  Mitochondrial biogenesis  
Oxidative phosphorylation  
Thermogenesis  
FA, fatty acid; SRC, steroid receptor coactivator; PGC-1, peroxisome proliferator-activated receptor γ 
coactivator-1 
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PPARγ coactivator-1 
Another family of coactivators is the PGC-1 gene family. The family consists of PGC-1 (116), 
the close homolog PGC-1 (121) and PGC-1-related coactivator (122). The domain structure 
of these coactivators is not homologous to that of the SRCs. PGC-1 contains a N-terminal 
activation domain, harbouring a LXXLL motif, as well as a C-terminal RNA binding domain 
and two serine and arginine rich regions. In addition PGC-1 has three consensus protein 
kinase A phosphorylation sites (116). The two other PGC-1 gene family members have a 
similar domain structure. 
PGC-1 does not have an intrinsic histone acetyl transferase activity, but interacts 
through its N-terminal activation domain with other coactivators that harbours such activity 
(123). Through its C-terminal RNA binding domain and serine/arginine rich regions PGC-1 is 
also found to form complex with the preinitiation and elongation forms of RNA polymerase II, 
as well as other elongation factors. Thus, PGC-1 function as a modulator of transcription 
initiation, elongation and mRNA processing of its target genes (124). 
PGC-1 is shown to be a transcriptional coactivator of many NRs, including the PPARs 
(116, 125, 126) and nuclear respiratory factors 1 and 2 (117), serving as a pleiotropic 
regulator of multiple pathways of cellular metabolism. Although there are similarities 
between the nature of PPAR interaction with PGC-1 compared to the interaction with SRC-1 
and SRC-2, there are also some differences. Both ligand dependent and independent 
interactions are observed, and PGC-1 also interacts through its LXXLL domain with the AF-2 
domain of PPARα and PPARδ (125, 126). However, weaker interactions have also been 
observed in the central hinge region of PPARα (126). In addition, PGC-1 interaction with 
PPARγ is demonstrated to be through a proline rich region of PGC-1 and the central hinge 
region or the DNA binding domain of PPARγ (116). 
When PGC-1 was identified as a PPARγ interacting protein in brown fat cells (116), it 
revealed a coactivator with major functions in energy homeostasis, Table 4. PGC-1 is 
expressed in brown fat, heart, kidney and brain. Upon cold exposure the mRNA expression of 
PGC-1 is induced in skeletal muscle, and the expression level in brown fat is increased (116). 
PGC-1 expression is induced in liver upon fasting, and in the liver of mice with diabetes, both 
insulin-deficient and insulin-resistant (120). In brown adipose tissue and skeletal muscle 
PGC-1 stimulates mitochondrial DNA production and induces mitochondrial respiration 
through increased expression of genes of the respiratory chain. In brown adipose tissue, 
mitochondrial uncoupling and thermogenesis are promoted through the induction of 
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uncoupling protein-1 (116), and mitochondrial uncoupling through uncoupling protein (UCP)-
2 is demonstrated in skeletal muscle (117). Through interaction with the PPARs, PGC-1 
stimulates the expression of genes involved in fatty acid oxidation in both muscle (118) and 
liver (119). Additionally, PGC-1 is demonstrated to control hepatic gluconeogenesis (120). 
 
Interaction between mitochondria, PPARs and coactivators  
The mitochondria are considered as the main cellular transducers of metabolic energy because 
they contain enzyme systems for fatty acid -oxidation, the citric acid cycle, ketogenesis, 
oxidative phosphorylation and thermogenesis. The mitochondrial function is closely 
connected to the activity of PPARs as several genes for proteins involved in mitochondrial 
function are considered as PPAR targets. These include the genes for proteins regulating fatty 
acid activation (ACS), mitochondrial fatty acid uptake (CPT-1 and CPT-2), -oxidation (acyl-
CoA dehydrogenase), ketogenesis (3-hydroxy-3-methylglutaryl (HMG)-CoA synthase), 
respiration and thermogenesis (cytochrome C, cytochrome oxidase, UCP-1 and UCP-2 ) (59, 
61, 62). By functioning as PPAR coactivators, SRC-1, SRC-2 and PGC-1 participate in 
linking the PPARs to mitochondrial function. In addition, especially PGC-1 may also play an 
independent role in stimulation of oxidative phosphorylation, mitochondrial thermogenesis 
and mitochondrial biogenesis (116, 117). The gene expression of PGC-1 is also reported to be 
induced by PPARδ activation (127). Thus, the function of mitochondria, PPARs and 
coactivators are interconnected and constitute important pathways relevant for regulation of 
obesity and obesity related disorders. 
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AIMS OF THE PRESENT STUDY 
The present thesis focuses on two modified fatty acids, TTA and TSA, with a biochemical 
and mechanistic angle to the description and possible therapeutic options of obesity related 
disorders and risk factors of the metabolic syndrome and cardiovascular disease. As major 
regulators of lipid metabolism and their involvement in glucose metabolism and inflammation, 
the PPARs have been in focus in these studies. 
 
Specific aims of this study have been to: 
 
 Elucidate the mechanisms behind tamoxifen-induced fatty liver, and evaluate the potential 
of TTA to prevent this development in combinatory treatment with tamoxifen. 
 
 Investigate the hypolipidemic effects of TTA in a clinical study in patients with type 2 
diabetes mellitus, and to consider the role of PPARs and mitochondrial fatty acid 
oxidation in these effects. 
 
 Evaluate the role of PPARα in mediating the hypolipidemic effects of TTA, and to study 
the role of PPAR coactivators in TTA-dependent and -independent PPAR activation. 
 
 Evaluate the potential antioxidant, antiinflammatory and hypolipidemic properties of TSA 
and to consider the role of PPARs and mitochondrial fatty acid oxidation in these effects. 
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EXPERIMENTAL MODELS 
In experimental science considerations are always made in regards to finding model systems 
that allow the design of efficient and effective methods that make it possible to pinpoint the 
relevant questions and to extrapolate the results into the relevant context. In the present 
studies, several different model systems have been employed, including several in vitro cell 
models, in vivo animal models and a phase II clinical study in patients with T2DM.  
 
Cell cultures 
The ability to culture cells in vitro provides a valuable technique for studying living cells 
under controlled conditions. Cell lines originating from various tissues and species are 
commercially available and have to a great extent contributed to our understanding of 
molecular interactions between proteins and regulatory mechanisms in metabolism. In the 
present investigation various cell culture models were used with respect to relevant tissues or 
to feasibility and simplicity of certain methods.  
 
Human HepG2 liver and MCF-7 breast cancer cells; transfection and gene expression studies 
(Papers II, III and IV) 
HepG2 cells are human liver cancer cells. It is a well established cell line that is easy to 
handle and to propagate, and widely used in basic scientific research. Although it is a cancer 
cell line and therefore harbours certain dissimilarities to primary human liver cells (cf. 
www.atcc.org), HepG2 cells are intended to be a model for liver tissue in the present studies. 
As the availability of primary human liver cells is rather limited and their propagation in cell 
cultures not straight forward, HepG2 cells have functioned as an easy-access and simple 
model with a stable phenotype for in vitro analyses. 
 The MCF-7 cells represents a human breast cancer cell line, which in the same way as 
HepG2 cells are easy to handle and to propagate, and widely used in basic scientific research. 
 Transfection assays, where we have evaluated PPAR activation by TTA or TSA, have 
been involved in all of the papers including the HepG2 and MCF-7 cell lines. Not all cell 
cultures are suitable for the transfection procedure, but optimization procedures demonstrated 
that these cell lines were easy to transfect, and therefore they were natural choices for use in 
our transfection assays. Gene expressions by real time reverse transcriptase polymerase chain 
reaction (RT-PCR) have also been measured in these cells. The MCF-7 cells were only 
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employed in one study (Paper III) for comparison with HepG2 cells and the detection of cell 
type specific effects. 
 
Human skin fibroblasts and murine J774 macrophages; uptake of oxidised LDL (Paper IV) 
Human skin fibroblasts were obtained from biopsies of healthy individuals and since they 
mainly express receptors for native LDL and not oxidised LDL, they were employed in 
studies of radiolabelled LDL oxidation. 
Likewise, due to their high capacity of oxidised LDL uptake, and limited amount of 
native LDL receptors, the murine J774 macrophages were useful for measuring oxidised LDL 
uptake. An advantage of these cells is that they differentiate easily into mature macrophages 
without the need of any specific chemical induction. 
Radiolabelled LDL particles were oxidised in a cell free system in the presence or 
absence of TSA. The fibroblasts and macrophages made it possible to evaluate the degree of 
LDL oxidation by measuring the uptake of either oxidised or native radiolabelled LDL. 
 
Human peripheral blood mononuclear cells; cytokine release (Paper IV) 
Human peripheral blood mononuclear cells were isolated from blood samples from healthy 
blood donors, providing the ability to study processes in a controlled environment with 
relevance to the human situation. An immune response was stimulated by the addition of 
phytohemagglutinin, lipopolysaccaride or TNFα, which are all commonly used agents for 
such a purpose. The way TSA treatment affected the release of proinflammatory and 
antiinflammatory cytokines was evaluated. 
 
Human skeletal muscle cells; mitochondrial fatty acid oxidation (Paper II) 
Human skeletal muscle cells were obtained from a previously established cell-bank of satellite 
cells from human muscle biopsies of healthy donors (128). The cells were employed in 
studies for mitochondrial fatty acid -oxidation and real time RT-PCR studies of fatty acid 
oxidation enzymes, where the effect of TTA was evaluated. As mentioned before, the use of 
primary cells derived from humans allows for the opportunity to measure several parameters 
in a controlled environment but still keeping the studies relevant for the human situation. The 
results from these cells were used as a supplement to the clinical study of patients with T2DM 
receiving TTA, in attempt to elucidate the TTA’s mechanism of action. 
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Animal-models 
In comparison to in vitro models, in vivo animal models represent an advantage in that it is 
possible to study whole body metabolism and to evaluate interaction and crosstalk between 
different tissues. All experiments with animal-models in this thesis (Papers I, III and IV) 
were conducted according to the Guidelines for the Care and Use of Experimental Animals. 
 
Sprague-Dawley rats; tamoxifen-induced fatty liver and cotreatment with TTA (Paper I) 
Tamoxifen is commonly used as an effective treatment for oestrogen receptor positive breast 
cancer (129), but is unfortunately associated with an increased risk of developing fatty liver 
(20, 21) through mechanism that are not yet fully elucidated. The hypolipidemic effects of 
TTA (25) make it a potential strategy in prevention of tamoxifen-induced fatty liver. 
In order to study the effect of tamoxifen on lipid metabolism in the liver in more detail, 
and to study the potential of TTA to prevent tamoxifen-induced fatty liver, we performed a 
study in female Sprague-Dawley rats from Taconic M&B A/S (Ry, Denmark). This is a 
traditional animal model used in virtually all disciplines of biomedical research. In order to 
resemble breast cancer patients, the rats were treated with a single dose of 20 mg of 7,12-
dimethylbenz[a]anthracene (DMBA; D-3254; Sigma-Aldrich Norway AS, Oslo, Norway) to 
induce cancer. 
 
Wistar rats; the antioxidant, antiinflammatory and hypolipidemic potential of TSA (Paper IV) 
In previous studies TSA has been demonstrated as a stronger antioxidant than TTA (28). We 
wanted to investigate if TSA also had antiinflammatory and hypolipidemic properties. As a 
complement to in vitro model systems for a model with higher relevance to the human 
situation, we employed another traditional and widely used rat model; male Wistar rats 
(Mol:Wist) from Møllegård Breeding Laboratorium (Ejby, Denmark). 
 
Domestic pigs; the potential of TSA to inhibit restenosis after percutaneous coronary 
intervention (Paper IV) 
Percutaneous coronary intervention is a therapeutic procedure to treat arteries that are 
narrowed due to the build-up of atherosclerotic plaque, and involves the inflation of a balloon 
within the coronary artery to crush the plaque into the walls of the artery. Restenosis is a 
common problem after this intervention, and the process of restenosis resembles the 
atherosclerotic process. Thus, studying restenosis after percutaneous coronary intervention 
provides an applicable model of the atherosclerotic process. 
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As the heart physiology of pigs is very similar to human heart physiology, this is an 
animal model with high relevance to humans in matters concerning the heart and the 
cardiovascular system. 
Highly qualified heart surgeons performed percutaneous coronary intervention in the 
arteries of healthy domestic pigs. Arterial injury was applied using an oversized semi 
compliant angioplasty balloon, and TSA was administered at the site of artery injury. This 
procedure allowed us to study the effect of TSA on processes that are linked to the 
development of atherosclerosis. 
  
PPARα-/- mice; the role of PPARα in hypolipidemic mechanisms mediated by TTA (Paper III) 
Genetic mutation models open an opportunity to obtain in depth knowledge about the 
functions of single targeted proteins in vivo. In order to get a better understanding of the 
specific role of PPARα in TTA mediated effect on lipid metabolism, we performed a study in 
PPARα-/- mice on a Sv/129 genetic background (130), with sv/129 mice as wild type control. 
The PPARα-/- mice have a targeted disruption of the PPARα gene, and are demonstrated to 
lack PPARα protein expression (130). The increased expression of PPARα target genes in 
response to PPARα ligands, as observed in wild type mice, is also absent in the PPARα-/- 
mice (130). Thus, these mice function as models to study the effect of PPARα deficiency. 
 
Open-label clinical study 
Due to the promising observations of TTA in regard to preventing risk factors of the 
metabolic syndrome in animal studies, we wanted to investigate if TTA was well tolerated 
also in humans, and if we could observe similar effects to those observed in animals. This first 
study performed with TTA in human patients was conducted with an open-labelled design 
(Paper II). This was an exploratory study of TTA in human patients, with safety as a major 
issue. Patients with T2DM received a daily morning dose of 1g TTA for 28 days (Paper II). 
Termination of other treatments (lipid lowering or hypoglycaemic drugs) was chosen to 
eliminate the risk of TTA/drug interactions. The study was performed in accordance with the 
Declaration of Helsinki and consistent with Good Medical Practise and applicable regulatory 
requirements.  
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SUMMARY OF THE PRESENT INVESTIGATION 
 
Paper I 
Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver. 
O. A. Gudbrandsen*, T. H. Rost*, and R. K. Berge. 
Journal of Lipid Research 2006; 47: 2223–2232. 
* equal contribution 
 
Objectives: 
Tamoxifen can induce hepatic steatosis in women. In this study, we wanted to elucidate the 
mechanism behind the tamoxifen-induced accumulation of triacylglycerol in liver in female 
rats, and we hoped to prevent this development by combination treatment with the modified 
fatty acid Tetradecylthioacetic acid (TTA). 
Results: 
We found that the increased hepatic triacylglycerol level after tamoxifen treatment was 
accompanied by decreased acetyl-coenzyme A carboxylase (ACC) and FAS activities, 
increased glycerol-3-phosphate acyltransferase (GPAT) activity, and a tendency to increased 
diacylglycerol acyltransferase (DGAT) activity. The activities and/or mRNA levels of 
enzymes involved in hepatic -oxidation, ketogenesis, and uptake of lipids were unaffected by 
tamoxifen, whereas the uptake of fatty acids was decreased. Combination treatment with 
tamoxifen and TTA (Tam+TTA) normalized the hepatic triacylglycerol level and increased 
the activities of ACC, FAS, GPAT, and DGAT compared with tamoxifen treated rats. The 
activities and mRNA levels of enzymes involved in -oxidation, ketogenesis, and uptake of 
lipids were increased after Tam+TTA treatment. 
Conclusions: 
In conclusion, tamoxifen increased the hepatic triacylglycerol level, probably as a result of 
increased triacylglycerol biosynthesis combined with unchanged -oxidation. The tamoxifen-
induced accumulation of triacylglycerol was prevented by cotreatment with TTA, through 
mechanisms of increased mitochondrial and peroxisomal -oxidation. 
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Paper II 
Tetradecylthioacetic acid attenuates dyslipidemia in type 2 diabetic patients, possibly by 
dual PPARα/δ activation and increased mitochondrial fatty acid oxidation 
Kristian Løvås, Therese H. Røst, Jon Skorve, Rune J. Ulvik, Oddrun A. Gudbrandsen, Pavol Bohov, Andreas J. 
Wensaas, Arild C. Rustan, Rolf K. Berge, Eystein S. Husebye. 
Submitted to Diabetologia, April 2008. 
 
Objectives: 
The modified fatty acid, tetradecylthioacetic acid (TTA), is previously demonstrated to 
improve transport and utilization of lipids, and to increase mitochondrial fatty acid oxidation 
in animal and cell studies. The aim of the present study was to determine whether TTA 
treatment of patients with type 2 diabetes mellitus and dyslipidemia could improve lipoprotein 
profile and possibly blood glucose. Moreover, by performing in vitro experiments, we aimed 
to study the role of peroxisome proliferator-activated receptors (PPARs) in TTA’s mechanism 
of action. 
Results: 
Sixteen male type 2 diabetic patients received 1g TTA daily for 28 days in an open-labelled 
study, with measurement of parameters of lipid metabolism, glucose metabolism and safety. 
The mechanism of action was further investigated in a human liver cell line (HepG2) and in 
cultured human skeletal muscle cells (myotubes). Mean LDL cholesterol level declined from 
4.2 to 3.7 mmol/L (P = 0.0004), accompanied by increased levels of the HDL apo A1 and apo 
A2, and a decline in LDL/HDL ratio. Total fatty acid levels declined significantly, especially 
the polyunsaturated n-3 fatty acids docosahexaenoic acid (-13%, P = 0.001) and 
eicosapentaenoic acid (EPA) (-10%, P = 0.033). Glucose metabolism was not altered and the 
drug was well tolerated. In cultured liver cells TTA acted as a pan-PPAR agonist, with 
predominant PPAR	 and PPAR activation at low TTA concentrations. In cultured skeletal 
muscle cells, TTA and a PPAR agonist, but not the PPAR	 or PPARγ agonists, increased the 
mitochondrial fatty acid oxidation.  
Conclusions: 
We demonstrate for the first time that TTA attenuates dyslipidemia in type 2 diabetic patients. 
The results suggest that these effects may occur through mechanisms involving PPARα and 
PPAR activation, resulting in increased mitochondrial fatty acid oxidation. 
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Paper III 
The pan-PPAR ligand, tetradecylthioacetic acid, induces hepatic fatty acid oxidation in 
PPARα-/- mice possibly through stimulation of PGC-1 dependent coactivation of 
PPARδ 
Therese H. Røst, Line L.H. Moi, Kjetil Berge, Bart Staels, Gunnar Mellgren, Rolf K. Berge 
Manuscript 
 
Objectives: 
Tetradecylthioacetic acid (TTA) is a hypolipidemic modified fatty acid, and ligand for 
peroxisome proliferator-activated receptor (PPAR)α, PPARδ and PPARγ. The mechanisms of 
TTA-mediated effects seem to involve the action of the PPARs, but the effects have not yet 
been assigned to any specific PPAR subtype. In PPARα-/- mice we wanted to study the role 
of PPARα after TTA treatment. We also performed in vitro experiments in order to obtain 
mechanistic knowledge of how TTA affected PPAR activation in the presence of the PPARγ 
coactivator (PGC)-1 and the steroid receptor coactivator (SRC)-1 and SRC-2, which have 
been associated with energy balance and mitochondrial biogenesis. 
Results: 
We show that TTA stimulates fatty acid -oxidation in PPARα-/- mice. In HepG2 and MCF-7 
cells TTA acts as a pan-PPAR ligand, and we demonstrate that PGC-1, SRC-1 and SRC-2 
have cell type and PPAR-specific effects in concert with TTA. In absence of exogenous 
ligands, SRC-1 did not induce PPAR activity. SRC-2 stimulated PPAR activity especially in 
MCF-7 cells, while PGC-1 was a far more potent PPAR coactivator in both cell lines. When 
the coactivators were overexpressed, pronounced effects of TTA were observed especially for 
PPARδ and PPARγ, but TTA further induced the PGC-1 dependent coactivation of only 
PPARδ. 
Conclusions: 
We conclude that PPARα is involved in, but not required for the hypolipidemic mechanisms 
of TTA. It appears that the activity of PPARδ, with a substantial contribution of nuclear 
receptor coactivators, PGC-1 in special, is conductive to TTA’s mechanism of action. 
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Paper IV 
Tetradecylselenoacetic Acid, a PPAR Ligand With Antioxidant, Antiinflammatory, and 
Hypolipidemic Properties 
Endre Dyrøy*, Therese H. Røst*, Reidar J. Pettersen, Bente Halvorsen, Oddrun A. Gudbrandsen, Thor Ueland, 
Ziad Muna, Fredrik Müller, Jan E. Nordrehaug, Pål Aukrust, Rolf K. Berge 
* equal contribution 
Arteriosclerosis, Thrombosis, and Vascular Biology 2007;27:628-634. 
 
Objectives: 
Antioxidants protect against oxidative stress and inflammation, which, in combination with 
hyperlipidemia, are important mediators of atherogenesis. Here we present a selenium-
substituted fatty acid, tetradecylselenoacetic acid (TSA). The objective of the present study 
was to evaluate the antioxidant, antiinflammatory and hypolipidemic properties of TSA, and 
to consider the role of PPARs and mitochondrial fatty acid oxidation in these effects. 
Results: 
We show that TSA exerts antioxidant properties by delaying the onset of oxidation of human 
low density lipoprotein (LDL), by reducing the uptake of oxidized LDL in murine 
macrophages and by increasing the mRNA level of superoxide dismutase in rat liver. TSA 
also showed antiinflammatory effects by suppressing the release of interleukin-2 and -4, and 
increasing the release of interleukin-10 in human blood leukocytes. In addition, TSA 
decreased the plasma triacylglycerol level and increased the mitochondrial fatty acid -
oxidation in rat liver. In pigs, TSA seemed to reduce coronary artery intimal thickening after 
percutaneous coronary intervention. In HepG2 cells TSA activated all peroxisome 
proliferator-activated receptors (PPARs) in a dose-dependent manner. 
Conclusions: 
Our data suggest that TSA exert potent antioxidant, antiinflammatory and hypolipidemic 
properties, potentially involving PPAR-related mechanisms. Based on these effects, it is 
tempting to hypothesize that TSA could be an interesting antiatherogenic approach to 
atherosclerotic disorders. 
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GENERAL DISCUSSION 
Since life-style related disorders and the metabolic syndrome are increasingly prevalent in 
both children and adults in many parts of the world, extensive research is being conducted in 
hope to restrain and prevent this development. Common for these disorders are visceral 
obesity and dyslipidemia, lipid modulating agents are therefore considered to have a 
promising potential in treatment strategies. 
 The present thesis focus on two modified fatty acids, TTA and TSA, with a 
biochemical and mechanistic angle to the description and possible therapeutic options of some 
of the factors related to obesity and the metabolic syndrome. As major regulators of lipid 
metabolism and their involvement in glucose metabolism and inflammation, the PPARs have 
been in focus in these studies. 
 
The potential of TTA in disorders related to obesity and the metabolic syndrome 
Since TTA was developed in order to test a hypothesis related to peroxisome proliferation 
almost 20 years ago (22), this modified fatty acid has been proven as highly bioactive with 
pleiotropic effects, and especially as a potent regulator of lipid metabolism (25). Several cell 
culture and animal studies have revealed that through mitochondrial proliferation and 
increased catabolism of fatty acids, as well as through antiproliferative, antioxidant and 
antiinflammatory properties, TTA may have a major impact on disorders related to obesity 
and the metabolic syndrome (25). 
 
Tamoxifen-induced fatty liver and potential of combinatory treatment with TTA 
Tamoxifen is a widely used drug against breast cancer. An undesirable side-effect is, however, 
that tamoxifen may induce fatty liver and visceral fat accumulation (20, 21). Fatty liver and 
visceral obesity are associated with other components of the metabolic syndrome, and is a 
problem that needs attention. The mechanism of tamoxifen-induced fatty liver is not fully 
elucidated, but we (Paper I) and others (131, 132) have tried to come closer to an explanatory 
mechanism. 
We found that treatment with tamoxifen for 14 days in rats significantly increased 
hepatic triacylglycerols and serum transaminases which are indicators of liver damage (Paper 
I). The increased hepatic triacylglycerol level may be caused by increased biosynthesis, 
impaired fatty acid -oxidation, increased hepatic uptake, or reduced secretion of lipids from 
the liver, or by a combination of two or more of these factors. As also reported by others (131, 
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132), we found that the fatty acid synthase, and thus fatty acid biosynthesis, was decreased by 
tamoxifen treatment (Paper I). However, it seemed like the biosynthesis of triacylglycerol 
was increased in the liver after tamoxifen treatment (Paper I), this was accompanied with 
unchanged -oxidation and may explain the hepatic accumulation of triacylglycerols.  
Others have reported the decreased expression fatty acid synthase, with a consequent 
increase in malonyl-CoA which inhibits CPT-1 and fatty acid oxidation, as the primary cause 
of tamoxifen-induced fatty liver (132). Another group also demonstrated that tamoxifen was 
able to inhibit mitochondrial fatty acid -oxidation and CPT-1 activity (131). The discrepancy 
between these (131, 132) and our (Paper I) results may be explained by different 
experimental designs, including the choice of mice versus rats, female or male, healthy or 
cancerous, and probably most importantly the administered tamoxifen dose and length of 
treatment. 
The hepatic uptake of triacylglycerol seemed to be unaffected by tamoxifen treatment, 
as assessed by gene expression of LDL and VLDL receptors (Paper I). The increased liver 
triacylglycerol combined with reduced serum triacylglycerol, may suggest that the secretion 
of triacylglycerol from the liver was reduced, which has previously been observed after 
tamoxifen treatment (131). The secretion of triacylglycerol-rich VLDL was not measured 
directly, but the unchanged expression of apo B and arylacetamide deacetylase (AADA), 
which play important roles in VLDL assembly (133), indicated that hepatic VLDL secretion 
was not affected. However, increased secretion of VLDL has been observed by others without 
any change in AADA mRNA level (133) and post-translational regulation of apo B is of 
importance (134). Thus, direct measurement of VLDL secretion is needed to get a clear 
impression of the VLDL secretion after tamoxifen treatment. Importantly, tamoxifen is also 
demonstrated to accumulate in liver mitochondria, where it impairs mitochondrial respiration 
and mitochondrial DNA synthesis (131, 135). In addition to the possible mechanisms of 
reduced hepatic triacylglycerol secretion, decreased mitochondrial -oxidation and more 
severe impairment of mitochondrial function may be the mechanism of tamoxifen-induced 
fatty liver. 
In order to investigate if TTA could prevent tamoxifen-induced fatty liver, we treated 
rats with a combination of tamoxifen and TTA (Paper I). The tamoxifen-induced 
accumulation of hepatic triacylglycerol was prevented by cotreatment with TTA, although the 
hepatic lipid biosynthesis and uptake of lipids from the circulation seemed to be increased 
(Paper I). However, in comparison to rats receiving tamoxifen, those that received tamoxifen 
in combination with TTA showed increased hepatic -oxidation of palmitoyl-CoA. This was 
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accompanied by increased gene expression and/or activity of mitochondrial and peroxisomal 
fatty acid oxidation enzymes as well as increased levels of Krebs cycle intermediates and 
ketone bodies (Paper I). Consequently, the levels of hepatic triacylglycerols and serum 
alanine transaminase was normalised, and therefore, increased -oxidation seems to be the 
mechanism by which TTA may have a potential in prevention of tamoxifen-induced fatty 
liver. TTA is also a regulator of mitochondrial biogenesis and is demonstrated to increase 
mitochondrial respiration, mitochondrial proliferation, mitochondrial DNA content and 
mitochondrial DNA synthesis enzymes (136, 137). Thus, it is possible that TTA may 
counteract the influence of tamoxifen on mitochondrial function and thereby prevent 
tamoxifen-induced fatty liver.  
The ability of TTA to prevent tamoxifen-induced hepatic triacylglycerol accumulation 
makes it a possible candidate for cotreatment with tamoxifen in breast cancer patients, in 
order to prevent the development of fatty liver. Moreover, this property of TTA also indicates 
a promising potential in treatment of fatty liver related to the metabolic syndrome. 
 
Hypolipidemic effects of TTA in humans 
TTA got approval to be used in human clinical studies from the Norwegian Medicines 
Agency after no toxic effects were revealed in preclinical toxicology studies in dogs and rats 
(R.K. Berge, unpublished data). The first clinical safety study with TTA was performed in 
healthy men receiving TTA (200-1000 mg/day) for 7 days. This study demonstrated that TTA 
was well tolerated and no adverse side effects were observed (R.K. Berge, unpublished data). 
Later a study was conducted in HIV-infected patients receiving TTA for 4 weeks together 
with a cholesterol-lowering diet, resulting in hypolipidemic, antiinflammatory and no adverse 
side effects of TTA (138).  
Also in patients with T2DM, who received a daily 1g dose of TTA for 28 days (Paper 
II), all safety parameters remained within the normal range. In addition, a significant 
improvement in their serum lipid and lipoprotein profiles was observed, which is in 
accordance with earlier observations in rats (25). In animals, the serum triacylglycerol level is 
normally reduced after TTA treatment (25). A reduction in serum triacylglycerol levels was 
also observed in the dyslipidemic HIV-patients receiving TTA (138), and in another group of 
patients with dyslipidemia (unpublished data, Rolf K. Berge). However, there was only a 
tendency of reduced serum triacylglycerol levels in the patients with T2DM after 28 days of 
TTA treatment (Paper II). This tendency was supported by a reduction in serum apo B, 
which is associated with the triacylglycerol rich VLDL lipoproteins, (Paper II). The serum 
39 
level of vitamin E has previously been found to correlate with the serum triacylglycerol level 
(139, 140), and the lowered serum concentration of vitamin E found in the T2DM patients 
receiving TTA (Paper II), therefore adds to the likelihood of a reduced serum triacylglycerol 
level in these patients. Before TTA treatment, the patients entered a two-week wash out 
period of lipid lowering drugs. This period may have been too short and could therefore 
possibly conceal/disturb the potential triacylglycerol lowering effects of TTA. 
The National Cholesterol Education Program has identified LDL as the primary target 
for cholesterol-lowering therapy in order to reduce the risk of CVD (141). Additionally, HDL 
has been associated with a negative risk of CVD, and hence a reduced LDL/HDL ratio is 
beneficial. Indeed, total- and LDL-cholesterol was decreased after TTA treatment (Paper II), 
together with an improved (reduced) LDL/HDL ratio. In this study we also observed a 
decrease in apo B and an increase in apo A1, the main protein components of LDL and HDL 
respectively, after TTA treatment. Consequently, the apo B/apo A1 ratio was reduced, which 
is reported to be associated with reduced insulin resistance and risk for the metabolic 
syndrome and cardiovascular disease (142, 143). Although TTA improves insulin sensitivity 
in rats (144), we did not observe any effects on glucose metabolism in the type 2 diabetic 
patients after TTA treatment  (Paper II). Nevertheless, this study shows TTA as a lipid 
lowering agent in humans with T2DM. Together with the improved lipid profiles in 
dyslipidemic HIV patients (138) and another group of dyslipidemic individuals (unpublished 
data, R.K. Berge), these are uplifting and promising observations. 
 
The role of PPARs in mediating hypolipidemic effects of TTA 
The PPARs stimulate the transcription of a great variety of genes in a complex system where 
tissue specificity and overlapping functions between the PPARs are characteristics. The genes 
which are under PPAR regulation are involved in many aspects of lipid metabolism, glucose 
and energy balance, inflammation, differentiation and proliferation (Table 2), reviewed in 
(59-62). Many of these processes are also affected by TTA (25), and the effects of TTA have 
indeed been allocated to the function of PPARs, PPARα in special (25, 145). However, with 
the increasing understanding and focus on the role of PPARδ in fatty acid metabolism and 
regulation of the metabolic syndrome (62), and since TTA is demonstrated to be a pan-PPAR 
ligand in various cell lines (26, 27, 75) (Paper III), attention should also be put on PPARδ 
while interpreting the results of TTA treatment. 
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 In rats with DMBA-induced breast cancer TTA prevented hepatic tamoxifen-induced 
triacylglycerol accumulation (Paper I), probably through increased mRNA expression of 
ACO, CPT-1, CPT-2, CD36, HMG-CoA synthase and liver fatty acid binding protein, as well 
as increased mitochondrial and peroxisomal -oxidation of fatty acids. Liver fatty acid 
oxidation is normally coupled to the action of PPARα (Table 2), so is the expression of the 
above mentioned genes in the liver (61, 130). Thus, it seems like the effects of TTA at least in 
part is mediated through PPARα in the liver. 
 After TTA treatment the serum level of fibrinogen, a blood coagulation factor 
associated with CVD risk, was significantly reduced in patients with T2DM (Paper II). The 
expression of fibrinogen in human liver and HepG2 cells has previously been demonstrated to 
be repressed by PPARα (146), and similarly, in a clinical study where patients with impaired 
glucose tolerance were treated with fenofibrate (PPARα agonist), serum fibrinogen levels 
were reduced (147). Accordingly, this could also be regarded as a PPARα dependent effect of 
TTA. The reduced lipid levels, improved lipoprotein profiles and increased level of apo A1 
and apo A2 after TTA treatment (Paper II) are also in agreement with other clinical studies in 
patients with obesity related disorders treated with the PPARα agonist GW590735 (148) or 
fenofibrate (147, 149). As recently reported (148), the PPARδ agonist GW501516 also induce 
the same reduction in serum lipid levels and improvement of lipoprotein profiles in humans. 
Similarly, an increase in apo A1 and apo A2 have been reported in monkeys treated with 
GW501516 (82). The in vitro studies accompanying the clinical data (Paper II) show that 
TTA is a pan-PPAR ligand in liver HepG2 cells, and that in human muscle cells the 
expression of CPT-1 and CD36, which are regulated by PPARδ in this tissue (148, 150), was 
increased. This may suggest a role of both PPARα and PPARδ in TTA mediated effects. 
Studies in mice revealed that PPARα was involved in, but not essential for increased 
fatty acid -oxidation by TTA in liver, as TTA also induced -oxidation in PPARα deficient 
mice (Paper III). Moreover, the hepatic PPARα expression is lower in humans compared to 
rodents (151), and since a dominant-negative splice variant of PPARα is present in human 
liver (151, 152) a more modest role of PPARα in human liver has been suggested (61).  This 
indicate that the role of PPARα in lowering hepatic lipid levels after TTA treatment may be 
less important, pointing in favour of other mechanisms, possibly involving PPARδ activation. 
In light of the above mentioned results (Papers II and III) (82, 146-150), the complexity of 
the PPAR system (Table 2), and the fact PPARδ has emerged as a major regulator of lipid 
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metabolism (62, 125, 153), it seems reasonable to believe that the activity of both PPARα and 
PPARδ, may be conductive to TTA’s mechanism of action.  
Some genes involved in lipid metabolism, such as ACO and CPT-1, are regulated by 
both PPARα (130, 154, 155) and PPARδ (62, 125, 148), but in different tissues. It has been 
demonstrated that PPARδ may compensate for the loss of PPARα in regulation of fatty acid 
homeostasis in skeletal muscle of PPARα knock out mice (156). It is possible that this also 
occurred in the liver of PPARα knock out mice treated with TTA (Paper III). The main 
function of PPARδ seems to be in skeletal muscle and adipose tissue, where increased fatty 
acid oxidation and improved mitochondrial function have been reported (62). The role of 
PPARδ in liver appears to be increased fatty acid synthesis at the expense of glucose levels 
(65), but decreased triacylglycerol accumulation in mouse liver is also observed after PPARδ 
activation (127). However, one study indicates that the expression of genes that are 
considered as PPARα targets in the liver is unaffected by PPARδ deficiency (157). In 
addition, contrary to the compensatory role of PPARδ in skeletal muscle of PPARα knock out 
mice (156), there are indications for a distinct role of PPARα and PPARδ in skeletal muscle, 
asserting that PPARδ may not cooperate or compensate for PPARα in this tissue (158).  
It has been demonstrated that pharmacological activation of PPARδ or PPARγ 
improves insulin sensitivity through different metabolic pathways (65). This suggests that 
PPARδ may also in other situations induce the same net effects as PPARα or PPARγ, 
although the mechanisms are not the same. Thus, in order to indicate with more certainty that 
PPARδ compensates for the loss of PPARα in liver, further studies are necessary to determine 
the specific role of PPARδ in liver, both in wild type and in PPARα deficient animals. 
PPARδ activation has in fact been demonstrated to induce the expression of PGC-1 (127). In 
this regard, focus should also be put on mitochondrial function.  
 
Coactivator dependent PPAR activity and the influence of TTA 
In order to approach a better mechanistic understanding of TTA’s actions, we studied the 
potential of TTA to stimulate PPAR coactivation by coactivators that are known to play a role 
in mitochondrial function and energy homeostasis; SRC-1, SRC-2 (114) and PGC-1 (116, 117) 
in two different cell lines; HepG2 and MCF-7 (Paper III). Cell type specific responses were 
observed, which is not unexpected considering the tissue specific roles of PPARs and 
coactivators in vivo (Tables 2 and 4). Similar for both cell lines was the potent coactivation 
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by PGC-1 and poor coactivation by SRC-1, while the combination of these two resulted in 
synergistic increase in the coactivation, except from PPARδ activation in MCF-7 cells (Paper 
III). Others have reported that PGC-1 is dependent on the interaction with SRC-1 for 
stimulation of PPARγ activity (114, 123), which is in contrast to our findings of the effects of 
PGC-1 alone on PPARγ, and which cannot be applied to our observations of PPARα or 
PPARδ either (Paper III). The discrepancy of these results is probably due to the complex 
PPAR system which is highly dependent on cell types and tissues (59, 61, 62), and the action 
of coactivators that may be equally complex (114, 116-120). 
 Addition of specific PPAR agonists or TTA led to minor stimulation of PPARα 
activity in presence of coactivators in both cell lines (Paper III). On the other hand, ligand 
responsive effects were observed for PPARγ and especially PPARδ. Worth noticing are the 
increased potency of the ligands in the presence of SRC-2 in MCF-7 cells, and the high level 
of PPARδ activation (200 fold) obtained by the addition of TTA or PPARδ specific agonist in 
PGC-1 overexpressing cells (Paper III). These in vitro results support that the activity of 
PPARδ, with a substantial contribution of NR coactivators, PGC-1 in special, might be an 
important part of TTA’s hypolipidemic mechanisms. With regards to the previous discussion 
of the role of PPARδ in liver lipid metabolism, it is possible that the PPARα independent 
effects of TTA in liver (Paper III) include PGC-1 dependent improvement on mitochondrial 
function and stimulation of mitochondrial biogenesis, thus contributing to increased 
mitochondrial -oxidation and lipid lowering. 
 
The antioxidant, antiinflammatory and hypolipidemic potential of TSA 
In an attempt to find a stronger antioxidant than TTA, the modified fatty acid TSA was 
developed by inserting a selenium atom in the 3-position of the carbon backbone, as selenium 
is a stronger reducing agent than sulphur. TSA is far less studied that TTA, but as 
hypothesised, the stronger antioxidant properties of TSA was confirmed in studies performed 
in vitro (28). In the present study (Paper IV) we confirmed the antioxidant effects of TSA 
and further explored if TSA could hold antiinflammatory and hypolipidemic properties. In 
activated immune cells isolated from humans, TSA repressed the release of the 
proinflammatory interleukin (IL)-2 and increased the release of the antiinflammatory IL-10 
(Paper IV). The release of IL-4, which is traditionally considered as an antiinflammatory 
cytokine, was also decreased (Paper IV). However, studies have indicated both 
proinflammatory and proatherogenic roles of IL-4 (159-162). Accordingly, the net effect of 
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TSA mediated cytokine release from activated human immune cells seems to be 
antiinflammatory, with a potential to be antiatherogenic as well. As pro-oxidants may play a 
role in the pathogenesis of inflammation (163), it is possible that the antiinflammatory effects 
of TSA is a consequence of its antioxidant properties. However, with respect to the relevance 
of PPARs in inflammation, and that the observed antiinflammatory properties of TSA in part 
coincide with the effects of PPAR activation (164-166), it was interesting to observe that TSA 
functioned as a pan-PPAR ligand in HepG2 cells (Paper IV). Moreover, the antioxidant 
actions of TSA, including reduced LDL oxidation and increased expression of superoxide 
dismutases, are also previously demonstrated to occur after PPARα and PPARγ activation 
(147, 167). 
 In addition to the antioxidant and antiinflammatory properties of TSA, we found that 
TSA was able to increase hepatic mitochondrial fatty acid -oxidation and decrease the level 
of plasma lipids in rats (Paper IV), which are also known effects of TTA (25). The rats were 
treated with fairly low TSA doses (8-25 mgKg-1day-1), compared to the usual TTA dose (150-
300 mgKg-1day-1) in animal studies, indicating that TSA might be a more potent 
hypolipidemic agent than TTA. The TSA mediated lipid lowering may be explained by 
increased expression of the PPAR target genes, ACO, CPT-1 and CPT-2 in vivo, supported 
by increased expression of the PPAR target genes ACO and CD36 in vitro (Paper IV). Thus, 
it seems like both TTA and TSA may function through PPAR dependent pathways.  
 Percutaneous coronary intervention is a therapeutic procedure to treat arteries that are 
narrowed due to the build-up of atherosclerotic plaque. Restenosis may follow after this 
procedure, and includes some of the same characteristics as atherosclerosis, involving 
inflammation, oxidative stress and increased proliferation of smooth muscle cells in the 
arterial wall (14, 29). In the arteries of pigs after percutaneous coronary intervention, TSA 
prevented smooth muscle cell proliferation and arterial intimal thickening (Paper IV), this is 
also an effect observed after PPARα activation (168). This observation, together with the 
potential of TSA in counteracting oxidative events, inflammation and hyperlipidemia, which 
are classified as atherosclerotic risk factors, point towards TSA as an interesting agent for 
further exploration of anti-atherosclerotic potential. The role of PPARs in this context should 
also be considered. 
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Some methodological considerations 
In vitro fatty acid administration 
The cellular fatty acid uptake of fatty acids administered bound to bovine serum albumin 
(BSA) and unbound fatty acids has previously been examined (169). It was demonstrated that 
at concentrations of 200 µM and 500 µM the cellular uptake, and hence the toxicity, of BSA 
bound fatty acids were significantly lower than unbound fatty acids (169). In some assays of 
Paper IV, TSA was administered at such high doses (100 µM and 500 µM), but in complex 
with BSA. The BSA complex and the measurement of cell viability after treatment enabled us 
to rule out toxic effects of TSA in these assays. In other parts of the present investigation 
(Papers II, III and IV) TTA or TSA were administered at lower doses dissolved in either 
ethanol or dimethylsulfoxide, and toxicity of the solvent in the cell media was prevented by 
keeping the solvent concentration low (0.1 % v/v). 
 
Transient transfection studies and real time RT-PCR 
An important part of the papers in this thesis has been to evaluate the effect of TTA and TSA 
on PPAR dependent transcriptional activity and the mRNA expression of known PPAR target 
genes. The approach to these tasks was to perform luciferase reporter driven transient 
transfection assays, and quantitative real-time RT-PCR. 
Transient transfection studies with a firefly luciferase reporter (Papers II, III and IV), 
evaluating PPAR dependent transcriptional activity, was carried out by the SuperFect (Qiagen) 
procedure, optimised for each cell line. The method allowed for simple analysis of PPAR 
dependent transcriptional activity in multi-well format with the capacity of analysing several 
parameters at the same time. The advantage of firefly luciferase as a reporter is the high 
efficiency and sensitivity (170).  
A limitation of this method could be the influence of exogenous ligands on 
endogenous cellular processes that may influence endogenous ligands and 
coactivators/corepressors, and subsequently affect the PPAR dependent transcriptional 
response. Thus, although these data provide valuable indications of PPAR activity, the results 
must be interpreted keeping in mind that the observed PPAR response probably results from 
the combined action of the direct binding of the exogenous ligands, and the indirect effects of 
endogenous ligands and coactivators/corepressors (84). 
By accompanying the transfection assays with RT-PCR analysis of the expression of 
PPAR target genes, the results can be interpreted with more certainty. In most of the present 
studies, quantitative real time RT-PCR was used for evaluation of mRNA expression. 
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SYBRgreen (Paper II) and TaqMan probes (Papers I, III, and IV) were used as the 
detectable quantifying units, allowing for high sensitivity and specificity (171). Primers and 
probes were normally designed so that the amplicons cross over exon-exon junctions, 
favouring cDNA and not genomic DNA amplification (171). 
 
 
CONCLUSIVE REMARKS 
The present thesis has presented two modified fatty acids, TTA and TSA, which are 
demonstrated to have a possible therapeutic potential in obesity related disorders and risk 
factors of the metabolic syndrome and cardiovascular disease. Their mechanism of action 
seems to include the action of PPARs, with contribution of NR coactivators. 
 
Based on the results presented in this thesis, the following can be concluded: 
 
 Increased hepatic triacylglycerol accumulation after tamoxifen is probably a result of 
increased triacylglycerol biosynthesis combined with unchanged -oxidation. TTA 
prevented this development through mechanisms of increased mitochondrial and 
peroxisomal -oxidation in the liver. 
 
 TTA has hypolipidemic effects in patients with T2DM, through mechanisms that seem to 
involve PPAR activation and increased mitochondrial fatty acid oxidation. 
 
 PPARα is involved in, but not essential for the hypolipidemic mechanisms of TTA in rat 
liver. A dual action of PPARα and PPARδ, with substantial contribution of NR 
coactivators, and a subsequent increased mitochondrial function appears to be TTA’s 
mechanism of action. 
 
 TSA exert potent antioxidant, antiinflammatory and hypolipidemic properties through 
mechanisms that are potentially related to increased PPAR activity and mitochondrial 
fatty acid oxidation. 
46 
FUTURE PERSPECTIVES 
This thesis provides evidence that TTA and TSA may have a therapeutic potential in obesity 
related disorders and risk factors of the metabolic syndrome and cardiovascular disease. TTA 
has been extensively studied in cells, animals (i.a. Paper I) and in an exploratory study in 
patients with T2DM (i.a. Paper II), and have provided us with conviction to perform future 
studies in humans. At present, the individual components of the metabolic syndrome are 
treated separately; i.e., statins are used for elevated cholesterol, fibrates are used to reduce 
triacylglycerol, and metformin and thiazolidinediones are used for hyperglycaemia. The wide 
range of beneficial effects suggested by the response to TTA, calls for larger long-term 
studies in patients for the treatment of hyperlipidemia, liver fat accumulation, obesity, and 
insulin resistance.  
 In order to get a more detailed understanding of TTA’s mechanism of action, further 
studies should also be performed in cells and animals. The specific roles of PPARs should be 
further investigated, as should PPAR independent mechanisms such as mitochondrial function. 
In vitro RNA interference techniques for gene silencing could be useful in order to specify the 
roles of PPAR subtypes in specific cell types. Knock out animals could also be valuable 
model systems in this respect. Concerning the studies of how TTA affects PPAR activation 
and coactivation (Paper III) by coactivators, some questions remain unanswered. It is still 
unknown how the interactions between PPARs and coactivators or between two coactivators 
are influenced by TTA. Amongst other methods Chromatin Immunoprecipitation (ChIP) 
assays will be appropriate for this approach. As cell type specific effects have been observed 
with TTA in PPAR activation assays, future studies should also consider this. 
TSA was developed as a spin-off of TTA in order to see if the chemical properties of 
the modifying atom could be reflected in the biochemical properties of the fatty acid. TSA has 
been less studied than TTA, but promising results in regards to oxidative stress, inflammation 
and hyperlipidemia have been observed (Paper IV), and suggests that TSA deserves future 
attention. Further studies in cells and animals are needed before TSA are clarified for human 
studies. As with TTA, it will also be interesting to get further insight in TSA’s mechanism of 
action, involving both PPAR-dependent and PPAR-independent mechanisms. 
The occurrence of obesity related disorders and risk factors of the metabolic syndrome 
and cardiovascular disease are steadily increasing all over the world. In this regard, it will be 
interesting to follow TTA and TSA in future studies with the overall aim to find therapeutic 
alternatives. 
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ERRATA 
Thesis 
Page 34, results, line 7: 
“, but” should be replaced by “.” and “only” should be removed. 
 
Page 34, results, line 8: 
After “PPARδ” the following should be inserted: “and PPARγ. In MCF-7 cells the effect was 
most pronounced on PPARδ”. 
 
Paper I 
Page 2223, abstract, line 13: 
“from” should be replaced by “to”. 
 
Page 2224, first column, line 25: 
“nitric oxide” should be replaced by “nitrous oxide” 
 
Page 2224, second column, lines 10-13: 
“; And glyceraldehyde-3-phosphate dehydrogenase forward (59-TGC ACC ACC AAC TGC 
TTA GC-39) reverse (59-CAG TCT TCT GAG TGG CAG TGA TG-39) and probe (59-TGG 
AAG GGC TCA TGA CCA CAG TCC A-39)” should be removed. 
 
Page 2224, second column, line 30: 
“(p/n: 4308313, Applied Biosystems)” should be inserted after “glyceraldehyde-3-phosphate 
dehydrogenase”. 
 
Paper II 
Page 6, line 3: 
“PAPRδ” should be replaced by “PPARδ”. 
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Paper III 
Page 3, line 13: 
The first “PPARγ” should be replaced by “PPARδ” so that the list of PPARs says “PPARα, 
PPARδ or PPARγ”. 
 
Page 9, line 2 from the bottom: 
“and PPARγ” should be inserted after “PPARδ”, and “PPARδ activity” should be inserted 
after “reaching”. 
 
Page 10, discussion, lines 4-5: 
“and PPARγ” should be moved to after “PPARδ”. 
 
Page 12, line 5 from the bottom: 
“and PPARγ” should be inserted after “PPARδ”. 
 
Paper IV 
Supplemental materials and methods, page 8, line 4: 
“and serum transaminases” should be removed. 
 
Supplemental materials and methods, page 9, line 15: 
“NO” should be replaced by “N2O”. 
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